GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Equity-to-Asset

Calidi Biotherapeutics (Calidi Biotherapeutics) Equity-to-Asset : -1.97 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Calidi Biotherapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-14.57 Mil. Calidi Biotherapeutics's Total Assets for the quarter that ended in Mar. 2024 was $7.41 Mil.

The historical rank and industry rank for Calidi Biotherapeutics's Equity-to-Asset or its related term are showing as below:

CLDI' s Equity-to-Asset Range Over the Past 10 Years
Min: -27.15   Med: -7.79   Max: -0.06
Current: -1.97

During the past 4 years, the highest Equity to Asset Ratio of Calidi Biotherapeutics was -0.06. The lowest was -27.15. And the median was -7.79.

CLDI's Equity-to-Asset is ranked worse than
94.17% of 1560 companies
in the Biotechnology industry
Industry Median: 0.67 vs CLDI: -1.97

Calidi Biotherapeutics Equity-to-Asset Historical Data

The historical data trend for Calidi Biotherapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Equity-to-Asset Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-12.14 -9.32 -19.42 -0.82

Calidi Biotherapeutics Quarterly Data
Dec20 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only - -6.26 -0.06 -0.82 -1.97

Competitive Comparison of Calidi Biotherapeutics's Equity-to-Asset

For the Biotechnology subindustry, Calidi Biotherapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calidi Biotherapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's Equity-to-Asset falls into.



Calidi Biotherapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Calidi Biotherapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-8.235/10.019
=

Calidi Biotherapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=-14.573/7.405
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calidi Biotherapeutics  (AMEX:CLDI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Calidi Biotherapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines